April 01, 2021
Article
The companies are now seeking a Biologics License Application with the FDA, which would allow it to become more greatly available for adults in the US.
March 31, 2021
The pivotal phase 3 data, based off 18 reported cases among placebo patients, includes the companies' intention to request authorization for adolescents aged 12-15 years old.
March 29, 2021
Cases have increased by 16%, while 50 million have now been fully vaccinated. Federal leadership is asking Americans to hold on longer.
March 23, 2021
A statement hours after the company reported promising interim phase 3 data stated the Data Safety and Monitoring Board believes they included outdated data “which may have provided an incomplete view of the efficacy data.”
March 22, 2021
After a year of setbacks, AZD1222 has been associated with 100% prevention of severe COVID-19 in US trial participants. Could emergency authorization come soon?
March 15, 2021
Phase 1/2 trial results showed the immunomodulary vaccine regimen could induce significant T-cell response in patients with HIV.
March 12, 2021
The data additionally show a 94% prevention against asymptomatic SARS-CoV-2 infection, at a time when the country's dominant strain was the B.1.1.7 variant.
Though the product is authorized more than 70 countries, there is currently no reported US trial data, nor application for authorization to the FDA.
March 10, 2021
The acquisition of the Johnson & Johnson pharmaceutical company's vaccine would likely be completed in the latter half of this year.
March 09, 2021
A UK health authority representative discussed the possibility of a fall season booster to prevent another winter surge of cases.
